FDMT - 4D Molecular Therapeutics Inc
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US35104E1001
Genetic, Eye, Heart, Lung, Disease
4D Molecular Therapeutics, Inc. is a clinical-stage biotherapeutics company that leverages its innovative therapeutic vector evolution platform to develop genetic medicines. With operations in the Netherlands and the United States, the company is dedicated to creating a portfolio of product candidates that address unmet medical needs in three key therapeutic areas: ophthalmology, cardiology, and pulmonology.
The company's product pipeline is robust, with several candidates in various stages of clinical development. 4D-150, for instance, is being evaluated in phase 1/2 clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema. Meanwhile, 4D-125 is being developed to treat x-linked retinitis pigmentosa, and 4D-110 is being investigated for the treatment of choroideremia. Additionally, 4D-710 is being developed to treat cystic fibrosis lung disease, and 4D-310 is being explored for the treatment of Fabry disease cardiomyopathy. All of these candidates are currently in phase 1/2 clinical trials.
Beyond its clinical-stage candidates, 4D Molecular Therapeutics also has several pre-clinical programs in development. 4D-175, for example, is being developed to treat geographic atrophy, while 4D-725 is being investigated for the treatment of alpha-1 antitrypsin deficiency lung disease. The company's commitment to innovation and collaboration is evident in its partnerships with leading organizations such as Arbor Biotechnologies, Inc., Astellas Gene Therapies, Inc., uniQure biopharma B.V., and the Cystic Fibrosis Foundation.
Founded in 2013, 4D Molecular Therapeutics, Inc. is headquartered in Emeryville, California, and is poised to make a significant impact in the field of genetic medicine. With its cutting-edge platform and robust product pipeline, the company is well-positioned to address some of the most pressing unmet medical needs of our time.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
FDMT Stock Overview
Market Cap in USD | 796m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2020-12-11 |
FDMT Stock Ratings
Growth 5y | -39.0 |
Fundamental | -72.2 |
Dividend | 0.00 |
Rel. Performance vs Sector | -6.54 |
Analysts | 4.55/5 |
Fair Price Momentum | 12.54 USD |
Fair Price DCF | - |
FDMT Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
FDMT Growth Ratios
Growth 12m | -3.83% |
Growth Correlation 12m | 40% |
Growth Correlation 3m | -80% |
CAGR 5y | -23.22% |
CAGR/Mean DD 5y | -0.39 |
Sharpe Ratio 12m | -0.08 |
Alpha vs SP500 12m | -45.36 |
Beta vs SP500 5y weekly | 2.04 |
ValueRay RSI | 44.34 |
Volatility GJR Garch 1y | 86.80% |
Price / SMA 50 | -14.71% |
Price / SMA 200 | -31.84% |
Current Volume | 370.2k |
Average Volume 20d | 458.2k |
External Links for FDMT Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of September 08, 2024, the stock is trading at USD 15.07 with a total of 370,185 shares traded.
Over the past week, the price has changed by +0.40%, over one month by -2.77%, over three months by -33.23% and over the past year by -5.16%.
According to ValueRays Forecast Model, FDMT 4D Molecular Therapeutics Inc will be worth about 14.3 in September 2025. The stock is currently trading at 15.07. This means that the stock has a potential downside of -5.11%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 50.3 | 234 |
Analysts Target Price | 35.4 | 135 |
ValueRay Target Price | 14.3 | -5.11 |